LTRN vs. CYBN, DMAC, NVCT, PBYI, ACRS, ENGN, CCCC, ACOG, BDTX, and ALEC
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Cybin (CYBN), DiaMedica Therapeutics (DMAC), Nuvectis Pharma (NVCT), Puma Biotechnology (PBYI), Aclaris Therapeutics (ACRS), enGene (ENGN), C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Black Diamond Therapeutics (BDTX), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry.
Lantern Pharma vs. Its Competitors
Lantern Pharma (NASDAQ:LTRN) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.
Cybin's return on equity of -37.58% beat Lantern Pharma's return on equity.
Lantern Pharma currently has a consensus price target of $25.00, suggesting a potential upside of 520.35%. Cybin has a consensus price target of $85.00, suggesting a potential upside of 999.61%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Lantern Pharma.
Lantern Pharma has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
In the previous week, Lantern Pharma had 1 more articles in the media than Cybin. MarketBeat recorded 3 mentions for Lantern Pharma and 2 mentions for Cybin. Cybin's average media sentiment score of 0.79 beat Lantern Pharma's score of -0.33 indicating that Cybin is being referred to more favorably in the news media.
28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 7.3% of Lantern Pharma shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Lantern Pharma is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.
Summary
Cybin beats Lantern Pharma on 9 of the 14 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantern Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:LTRN) was last updated on 7/22/2025 by MarketBeat.com Staff
